Key result
Pioglitazone evaluated against glimepiride for effects on carotid intima-media thickness in type 2 diabetes.
Why the study?
Patients with type 2 diabetes mellitus have a markedly increased risk of myocardial infarction and a worse post-MI prognosis, and their incremental risk for cardiovascular events remains high even with optimal control of blood pressure and LDL-C.
Answers are grounded in this paper and cite their sources.
Patients with type 2 diabetes mellitus (DM) have a marked increase in the risk of myocardial infarction (MI), and a substantially worse prognosis after MI compared with patients without diabetes.1–3 In recent years, it has become apparent that optimal control of blood pressure and low-density lipoprotein cholesterol (LDL-C) level can substantially reduce excess cardiovascular risk in patients with diabetes.4–6 However, even with optimal control of these potent cardiovascular risk factors, incremental risk for cardiovascular events remains high comp
No takes yet. Share an insight, caveat, or question.
Theodore Mazzone (2007) studied Type 2 diabetes mellitus. Pioglitazone vs. Glimepiride was evaluated on Carotid intima-media thickness. Pioglitazone compared with glimepiride was evaluated for its effect on carotid intima-media thickness in type 2 diabetes, though quantitative results are not provided in the truncated text.
Synapse has enriched 10 related papers. Consider them for comparative context: